Antidepressant patch emsam approved

The first maoi transdermal patch named emsam was developed by somerset pharmaceuticals. Place your emsam transdermal system patch on one of the following. Emsam is not approved for use by anyone younger than 12 years old. The emsam patch is a unique monoamine oxidase inhibitor maoi being the only antidepressant utilizing a transdermal delivery system. Emsam selegiline prevents the breakdown of chemicals in the brain that are often imbalanced in people with depression. When when applied to intact skin, emsam is designed to continuously deliver selegiline over a 24hour period. The lowestdose version of the patch contains six milligrams of emsam, a monoamine oxidase mao inhibitor.

Fda approves first antidepressant transdermal patch. Selegiline transdermal patch emsam for major depressive. The transdermal delivery system was believed to offer a number of unique advantages. The drug will be marketed as emsam, said somerset pharmaceuticals inc. Emsam systems are transdermal patches that contain 1 mg of selegiline per.

However, you may have a relapse of depression if you stop using your antidepressant. Emsam is the first antidepressant transdermal delivery system to receive food and drug administration fda approved labeling for the treatment of major depressive disorder mdd. Selegiline is an antidepressant monoamine oxidase inhibitor that treats depression by restoring the. The food and drug administration approved the selegiline transdermal patch, agency spokeswoman susan cruzan said. First emsam is not the name of the antidepressant itself but rather the name of the transdermal delivery system that is, a very high tech patch that contains an maoi called selegiline. A small number of children, teenagers, and young adults up to 24 years of age who took antidepressants mood elevators such as transdermal selegiline. The effect of direct heat applied to the emsam patch on the bioavailability of selegiline has not. Read the medication guide available from your pharmacist before you start using selegiline and each time you get a refill. Fda approves first antidepressant transdermal patch medpage. Although selegiline was never fdaapproved as an antidepressant in. Essential facts about antidepressants everyday health. Emsam transdermal patches are used to treat major depressive disorder in adults and adolescents who are at least 12 years old.

Because emsam is a patch that delivers the maoi selegiline through the skin, it avoids the medication passing through the stomach which was the danger area for problematic interactions with. When used at 6 mg over 24 hours, its lowest strength, the emsam patch does not carry the dietary restrictions that are necessary when using oral mao inhibitors. The fda approved the patch in 6, 9, and 12 mg doses that will be delivered transdermally over 24 hours. Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. The onceaday patch, called emsam, works by delivering selegiline, a monoamine oxidase inhibitor or. Antidepressant relief in a skin patch from the webmd archives nov. Federal regulators in the us have approved the worlds first antidepressant skin patch, the selegiline transdermal patch, to be marketed under the name emsam. Emsam may also be used for purposes not listed in this medication guide.

First antidepressant patch is approved new scientist. The selegiline transdermal patch emsam delivers higher, more. The drug, first approved in the 1980s to help treat parkinsons disease, belongs to a category of less frequently used antidepressants prone to interactions with a substance called tyramine. It should be noted that emsam is not approved for use in treating bipolar. Not all antidepressant medicines prescribed for children are fda approved for. Emsam transdermal patches are used to treat major depressive. Recently 2008, emsam rn, 2dimethyln2propynylphenethylamine, a maoi, was developed and approved as an alternative antidepressant with a novel transdermal delivery system. This approval was welcomed by academicians who believed that emsam would provide patients with the first antidepressant that had a new. Food and drug administration fda approved emsam, the first skin patch for treating major depression. The following adverse reactions have been identified during postapproval use of emsam. The patch provides one improvement, and selegiline gives another.